Company Overview

Travere Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for people living with rare diseases. The company operates within the biopharmaceutical and rare disease therapeutics industries, with a strategic emphasis on conditions with high unmet medical need and limited treatment options. Its core value proposition centers on advancing targeted, disease-modifying medicines supported by specialized commercial capabilities in rare and ultra-rare indications.

The company’s primary revenue driver is its approved and late-stage therapeutics portfolio, led by FILSPARI (sparsentan), a first-in-class dual endothelin and angiotensin receptor antagonist. Travere’s strategic positioning is based on deep expertise in rare renal and metabolic diseases, regulatory experience in orphan indications, and a focused commercial infrastructure. Founded in 2006 as Retrophin, Inc., the company rebranded as Travere Therapeutics in 2019 to reflect a broader mission of advancing transformative therapies, evolving from an acquisition-driven model to one centered on internal research, development, and commercialization.

Business Operations

Travere Therapeutics conducts its operations through a single, integrated reporting segment focused on rare disease therapeutics, encompassing research and development, regulatory affairs, and commercial operations. The company generates revenue primarily from product sales of FILSPARI, which received accelerated approval in the United States for the treatment of IgA nephropathy, and from remaining lifecycle management activities tied to its legacy products. Historically, Travere also marketed bile acid and cystinuria therapies, though it divested Cholbam and Chenodal as part of a strategic portfolio realignment.

Operationally, Travere maintains in-house clinical development, medical affairs, and commercial capabilities, while relying on third-party manufacturers for drug substance and drug product manufacturing. The company operates primarily in the United States, with international activities conducted through partners and distributors. Its asset base includes intellectual property rights related to sparsentan and associated clinical data, as well as regulatory exclusivity under orphan drug frameworks.

Strategic Position & Investments

Travere’s strategic direction is centered on maximizing the long-term value of sparsentan across multiple proteinuric kidney diseases, including IgA nephropathy and Alport syndrome. Growth initiatives focus on completing confirmatory clinical trials, pursuing full regulatory approvals, and expanding geographic reach through partnerships outside the United States. The company has publicly stated its intent to remain disciplined in capital allocation, prioritizing internal pipeline advancement over broad diversification.

In recent years, Travere streamlined its portfolio through the divestiture of non-core assets, including the sale of Cholbam and Chenodal to SERB Pharmaceuticals, allowing it to redeploy capital toward late-stage renal programs. The company’s pipeline strategy emphasizes rare renal diseases supported by precision medicine approaches, leveraging established regulatory pathways for orphan and accelerated approvals.

Geographic Footprint

Travere Therapeutics is headquartered in the United States, with its principal executive offices in California. Its primary commercial and clinical operations are concentrated in North America, where regulatory approvals and commercialization activities are most advanced. The company’s U.S. focus reflects the size of the rare disease market and the regulatory environment supporting orphan drug development.

Internationally, Travere has a limited direct operational presence and instead relies on strategic collaborations, licensing arrangements, and distribution partners to extend its reach into Europe and other select global markets. Clinical trial activities have included sites across multiple regions, providing the company with international regulatory engagement and data to support future global expansion.

Leadership & Governance

Travere Therapeutics is led by an executive team with experience in rare disease drug development, regulatory strategy, and commercialization. The leadership team emphasizes patient-centric development, scientific rigor, and disciplined execution, with a strategic vision focused on building a sustainable rare disease company anchored by high-impact therapies.

Key executives include:

• Thomas A. Wiggans – President and Chief Executive Officer
• Christopher A. Cline – Chief Financial Officer
• Eric Dube, M.D. – Chief Medical Officer
• Peter Karow – Chief Legal Officer and Corporate Secretary
• Suneel Gupta – Chief Commercial Officer

The company is governed by a board of directors with backgrounds in biotechnology, finance, and healthcare, providing oversight aligned with long-term shareholder value creation and regulatory compliance.